Cramer’s lightning round: Stay long Royalty Pharma

Business

Loading chart…

Royalty Pharma: “I can’t believe, sir, how low this stock is. … This company is doing so well. I really don’t know what to say. It is doing incredibly well. They ought to be able to raise the dividend, but they own stakes in a lot of different drugs. I would want to stay long this stock.”

Loading chart…

Canadian Pacific: “It’s a buy. I think it’s the laggard in the group because of the transaction. I mean, obviously you’ve seen what we’re doing with Union Pacific in the [CNBC Investing Club.] It’s been such a monster. I think that that railroad will be playing catch up to UNP.”

Loading chart…

Danaos: I’m not going to recommend containership stocks. … These are ones where I can look so great or so bad, and I’d rather just go with something consistent.”

Loading chart…

Standard Lithium: “I think it can go higher because parts of the battery are really in obvious demand, but I am sticking with my new fave: MP Materials.”

Loading chart…

Ionis Pharmaceuticals: “Doesn’t have enough juice for me. Never really started making a lot of money. I just can’t recommend them. I can’t. I like the ones we talked about [for the CNBC Investing Club] a lot more.”

Sign up now for the CNBC Investing Club to follow Jim Cramer’s every move in the market.

Disclaimer

Questions for Cramer?
Call Cramer: 1-800-743-CNBC

Want to take a deep dive into Cramer’s world? Hit him up!
Mad Money TwitterJim Cramer TwitterFacebookInstagram

Questions, comments, suggestions for the “Mad Money” website? madcap@cnbc.com

Products You May Like

Articles You May Like

In a reversal, the Education Department is now excluding some borrowers from student loan relief
Cramer’s lightning round: nLight is not a buy
Stocks making the biggest moves midday: Wynn Resorts, Planet Fitness, AMC, Lyft and more
‘The Woman King’ shows why the box office needs more mid-budget movies
The union push could face a big obstacle in 2023 if the economy falls into a recession

Leave a Reply

Your email address will not be published.